QuantiFERON-TB Gold Plus Test
Qiagen · Decision date Nov 21, 2025
What did the FDA approve?
FDA records P010033/S051 as a supplement to PMA P010033, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Nov 21, 2025.
FDA approval order statement
Approval for a design change to the device TB Antigen blood collection tubes (QuantiFERON TB Gold Pro Blood Collection Tubes) with the QuantiFERON-TB Gold Plus Test
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Microbiology
- Decision date
- Nov 21, 2025
- FDA change category
- Change Design/Components/Specifications/Material
Regulatory record facts
- Identifier
- P010033/S051
- Regulatory pathway
- PMA supplement
- Applicant
- Qiagen
- Product code
- NCD
- Decision code
- APPR
- Decision date
- Nov 21, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: TEST, IMMUNITY, CELL MEDIATED, MYCOBACTERIUM TUBERCULOSIS.
For the original device and its historical approval scope, see PMA P010033. Subsequent supplements may change the device or its indications.
FDA decision timeline
P010033 · Original PMA
QUANTTFERON-TB GOLD AND TB GOLD-IN-THE-TUBE
P010033/S051 received
Application receipt date recorded by FDA.
P010033/S051 · FDA decision
Real-Time Process
P010033/S052 · Related supplement
QuantiFERON-TB Gold Test and QuantiFERON-TB Gold Plus Test
P010033/S053 · Related supplement
QuantiFERON-TB Gold Plus Test
Timeline entries are records held by MedtechLedger for P010033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P010033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Qiagen | PMA approval | Nov 28, 2001 | FDA | |
| Qiagen | PMA supplement | Jan 23, 2026 | FDA | |
QuantiFERON-TB Gold Plus TestP010033/S053 | Qiagen | PMA supplement | Oct 14, 2026 | FDA |
Explore the linked device profile
Other records with product code NCD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LIAISON QuantiFERON-TB Gold Plus II.P180047/S046 | DiaSorin, Inc. | PMA supplement | Sep 24, 2026 | FDA |
| DiaSorin, Inc. | PMA supplement | Aug 27, 2026 | FDA | |
| DiaSorin, Inc. | PMA supplement | Aug 27, 2026 | FDA | |
| DiaSorin, Inc. | PMA supplement | May 26, 2026 | FDA | |
| DiaSorin, Inc. | PMA supplement | Jan 26, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Qiagen
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 19300 Germantown Rd., Germantown, MD, 20874
Sources and methodology
- Original FDA record: P010033/S051
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



